Reactions 1680, p325 - 2 Dec 2017 Liver dysfunction and cerebral infarction: 2 case reports In a retrospective, observational study of 21 patients, two patients [ages and sexes not stated] were described who developed liver dysfunction and cerebral infarction, respectively during therapy with tolvaptan [route and dosage not stated]. The patients with chronic kidney disease and congestive heart failure, received tolvaptan for excess body fluid. However, one patient developed liver dysfunction while another patient developed cerebral infarction during therapy with tolvaptan. Subsequently, tolvaptan was discontinued in both patients [durations of treatment to reactions onset and outcomes not stated]. Author comment: "Two cases were not able to continue use of tolvaptan because of its side effects". "Among 21 study participants, 2 patients discontinued tolvaptan treatment during the study periods because of liver dysfunction and cerebral infarction, respectively." Katsumata M, et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clinical and Experimental Nephrology 21: 858-865, No. 5, Oct 2017. Available from: URL: http://doi.org/10.1007/s10157-016-1379-0 - Japan 803283918 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera